Founded in 2016, the Institute has been instrumental in providing a space for the top researchers into cancer across different fields to collaborate and communicate on the latest breakthroughs in settings that range from formal meetings to informal retreats.
Parker suggested that rather than have each of these researchers spin their technologies out into separate companies that would develop one discrete innovation that would be needed to get to a cell-based therapy for solid tumors, the researchers should combine forces and build an arsenal of tools for the discovery and development of potential cures.
“I look at this as a tour de force of a combination of bringing academics together who typically would start separate companies and get them working together with a dream team management team,” says Beth Seidenberg, the founder of Westlake Village BioPartners and an investor in ArsenalBio.
Alongside the powerhouse executive team and scientific founders, ArsenalBio has now raked in $85 million in financing from investors including Westlake Village, the PICI, Kleiner Perkins, the Unversity of California, San Francisco Foundation Investment Company, Euclidean Capital and Osage Venture Partners.
T cell treatments have already shown amazing promise with certain types of cancer, but have not been able to effectively treat the solid tumors that represent the deadliest manifestation of the disease.